Anaphylaxis Pipeline Insight
DelveInsight’s, “Anaphylaxis – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaphylaxis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Anaphylaxis is an acute, potentially life-threatening hypersensitivity reaction to a trigger such as an allergy and involving the release of mediators from mast cells, basophils and recruited inflammatory cells. Anaphylaxis usually develops rapidly, reaching peak severity within 5 to 30 minutes, and may, rarely, last for several days. The term anaphylaxis is often reserved to describe immunological, especially IgE-mediated reactions. A second term, non-allergic anaphylaxis, describes clinically identical reactions that are not immunologically mediated. Allergies to food, insect stings, medications and latex are most frequently associated with anaphylaxis.
Signs and symptoms of Anaphylaxis can be defined alone or in combination, which occur within minutes, or up to a few hours, after exposure to a provoking agent. The symptoms of Anaphylaxis depends on the type of allergy and the trigger and may include: feeling lightheaded or faint, nasal congestion, breathing difficulties (such as fast, shallow breathing), wheezing, clammy skin, nausea and vomiting, diarrhea, collapsing or losing consciousness or swelling and itchiness of the skin etc.
A diagnosis of Anaphylaxis is made based upon a detailed review of patient’s allergic reactions history, and a variety of specialized tests. Diagnostic tests such as skin-prick tests, blood tests and oral food challenges are done to determine the particular triggers.
Emergency treatment for an Anaphylaxis patient with a severe allergic reaction involves an injection of epinephrine, or adrenaline. Epinephrine IM or IV is the first line treatment. Avoidance of trigger is the most effective way to prevent anaphylaxis. In some cases oxygen, beta-agonist (such as albuterol), intravenous antihistamines and cortisone are used to relieve breathing symptoms. One might receive cardiopulmonary resuscitation, if the patient stop breathing or if his or her heart stops beating.
- The companies and academics are working to assess challenges and seek opportunities that could influence Anaphylaxis R&D. The therapies under development are focused on novel approaches to treat/improve Anaphylaxis.
- In September 2020, ARS Pharmaceuticals announced that it has entered into an exclusive licensing agreement with Recordati for marketing rights in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, for ARS-1 (known as NeffyTM in the United States), an epinephrine nasal spray for Anaphylaxis.
Anaphylaxis Emerging Drugs Chapters
This segment of the Anaphylaxis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaphylaxis Emerging Drugs
AQST-108: Aquestive Therapeutics
AQST-108 is a “first of its kind” oral sublingual film formulation delivering systemic epinephrine using Aquestive’s proprietary PharmFilm® technologies. It is currently in Phase I development for the treatment of allergic reactions (Type 1), including anaphylaxis. In August 2020, USFDA has granted Fast Track designation to AQST-108.
NS-002: Nasus Pharma
NS-002 is an alpha and beta adrenergic receptor agonists. This Intransal Epinephrine formulation is in Phase II development for the treatment of anaphylactic shock.
Further product details are provided in the report……..
Anaphylaxis: Therapeutic Assessment
This segment of the report provides insights about the different Anaphylaxis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Anaphylaxis
There are approx. 8+ key companies which are developing the therapies for Anaphylaxis. The companies which have their Anaphylaxis drug candidates in the most advanced stage, i.e. phase II include, Hikma Pharmaceuticals.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Anaphylaxis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Anaphylaxis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaphylaxis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaphylaxis drugs.
Anaphylaxis Report Insights
- Anaphylaxis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Anaphylaxis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anaphylaxis drugs?
- How many Anaphylaxis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anaphylaxis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anaphylaxis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anaphylaxis and their status?
- What are the key designations that have been granted to the emerging drugs?